SLU-PP-332 Benefits: What the Research Actually Shows

The honest summary of the table: a well-characterised mouse pharmacology story, some of it tested to a higher standard than most compounds in this category, and nothing measured in a person.

SLU-PP-332 is a small synthetic organic molecule, built around a naphthalene ring and a phenol, designed to switch on the estrogen-related receptors ERRα, ERRβ and ERRγ. Despite the name, those receptors do not bind estrogen; they sit on DNA and control the genes that build mitochondria, run oxidative phosphorylation and oxidise fatty acids. In muscle, heart and kidney they are among the main switches the body uses to adapt to aerobic exercise. SLU stands for Saint Louis University, where the compound came out of a collaboration between medicinal chemists and the pharmacology group of Thomas Burris, published in ACS Chemical Biology in 2023. It is not a stimulant, not a thyroid hormone, not a GLP-1 medication, and does not act on appetite. Every benefit below hangs off the ERR story.

What the research describes. This is the founding result. In the 2023 ACS Chemical Biology paper, mice given SLU-PP-332 ran further and for longer on a treadmill than untreated mice. The mechanism was tested with knockout animals: mice engineered to lack ERRα did not show the effect. A 2026 paper in the Journal of Pharmacology and Experimental Therapeutics reproduced the endurance finding with the group's orally active successor compound, SLU-PP-915.

Evidence type. Animal.

Strength. The most rigorous of the SLU-PP-332 findings, because the knockout test links the effect to a specific receptor. It remains a mouse result. Nobody has measured endurance in a person given SLU-PP-332, and exercise mimetics have a history of working in rodents and failing to translate.

What the research describes. A single session of endurance exercise changes which genes muscle expresses in the hours afterwards. The 2023 paper reported that a dose of SLU-PP-332 in mice induced a strikingly similar set of genes, and that the response depended on ERRα. The 2026 JPET paper reported that one marker of that program, a gene called Ddit4, rose to levels matching or exceeding a treadmill run, depending on the muscle sampled. This is where the "exercise mimetic" label comes from.

Evidence type. Animal and cell.

What it means. The label describes a gene-expression pattern in mouse muscle. It does not mean the compound produces the full benefits of exercise, and the researchers who made it describe it as a candidate for people who cannot exercise adequately, not as a replacement for training in people who can. The 2026 JPET paper also reported that the oral successor's effect on mitochondrial gene expression was larger combined with exercise training than with either alone. How this compares with the other compounds sold under the same label is in MOTS-c vs SLU-PP-332 vs 5-Amino-1MQ.

What the research describes. ERRα and ERRγ, working with a coactivator protein called PGC-1α, control a large block of genes involved in mitochondrial biogenesis, the electron transport chain, the Krebs cycle and fatty acid oxidation. In a mouse skeletal-muscle cell line, the 2023 paper reported increased mitochondrial function and cellular respiration after treatment.

The human angle. A 2025 pilot study in Frontiers in Physiology took muscle cells from inactive women during hip surgery and treated them with SLU-PP-332 in culture. The cells showed changes in mitochondrial and stress-response proteins. That is human tissue in a dish, and the authors call for further work before drawing conclusions.

Evidence type. Cell, including human cells.

Strength. The only benefit with any human material behind it, and that material is cultured cells, not a person taking the compound.

What the research describes. Muscle fibres come in fast, glycolytic types that fatigue quickly and slower, oxidative types that keep going; endurance training shifts the balance toward the oxidative end. The 2023 work reported that treated mice had a higher proportion of type IIa oxidative fibres, the structural change the group proposed as the basis for the longer running times.

Evidence type. Animal.

Strength. One mouse study. Fibre type has not been measured in people given SLU-PP-332.

What the research describes. The 2024 paper in the Journal of Pharmacology and Experimental Therapeutics moved from muscle to whole-body metabolism. In diet-induced obese mice and in ob/ob mice, treatment was reported to raise energy expenditure and fatty acid oxidation, with less fat mass accumulated over the study. The authors' framing is that the compound shifts fuel preference toward fat, in the same direction regular aerobic exercise does.

Evidence type. Animal.

What it means. These are the results behind the compound's "weight loss" categorisation. They were measured in animals on controlled diets, at doses that do not map directly onto a compounded vial, and the mouse finding is less fat accumulated, not a measured loss in a person. SLU-PP-332 has no appetite mechanism. If losing weight is the main goal, semaglutide and tirzepatide have large randomised human trials with weight as the endpoint, and SLU-PP-332 has none. The best peptides for weight loss sets out the evidence gap plainly.

What the research describes. The same 2024 JPET paper reported that insulin sensitivity improved in the metabolic-syndrome mouse model.

Evidence type. Animal.

Strength. One mouse model, and no human glucose or insulin data of any kind. Anyone taking a glucose-lowering medication should list it on the intake, because there is no interaction data.

What the research describes. A 2024 paper in Circulation, from a group outside the original lab, reported that in a mouse model of pressure-overload heart failure, ERR agonists improved ejection fraction, reduced fibrosis and improved survival, with the effect tracing mainly to ERRγ in heart muscle cells. It used functional, genetic and multi-omics readouts and is the most rigorous single study of the compound.

Evidence type. Animal, disease model.

What it means. It says nothing about the heart of a healthy person taking the compound for a metabolic reason, which has not been studied. It also cuts both ways: because the compound acts on the heart's fuel metabolism, anyone with a cardiac history should say so at intake. SLU-PP-332 is not a treatment for heart disease.

What the research describes. A 2023 paper in the American Journal of Pathology reported that eight weeks of treatment in 21-month-old mice moved several age-related kidney measures, including albuminuria and inflammatory signalling, back toward those of younger animals, with no obvious harm reported.

Evidence type. Animal.

What it means. It is one of the few long-duration treatment studies, and the longest animal treatment on file, at eight weeks. It is a study of the ERRs as a caloric-restriction mimetic in old mice, not of SLU-PP-332 as a product, and it is not evidence of any kidney benefit in people.

What the research describes. Nothing directly. No study has measured energy, fatigue or stamina in people given SLU-PP-332.

What prescribers report. Steadier energy through the day is the earliest thing prescribers most often describe, if anything is reported at all; noticing nothing is also normal. The window prescribers point to for any change in stamina or body composition is weeks three to eight, on the reasoning that the animal fibre-type and fat-mass changes took weeks rather than days. These are patterns described by prescribers, not trial endpoints, and nobody can promise a timeline.

Evidence type. None direct.

• That any effect seen in mice occurs in humans. That question is open.
• A human dose. The mouse doses were set by body weight and given intraperitoneally.
• An effect size or a timeline for any benefit above. Anything said about "results by week six" is guessing.
• Safety in humans over any duration.
• Efficacy for any condition as an approved treatment. SLU-PP-332 is not approved for anything.

The accurate framing: a well-characterised mouse pharmacology tool, with no human evidence in either direction. Any source describing it as shown to work in people is describing something that has not been published.

Where SLU-PP-332 stands with the FDA

As of September 2026, SLU-PP-332 does not appear in any category of the FDA's list of bulk drug substances nominated for compounding under section 503A, updated 14 May 2026. It has never been flagged on the FDA's significant-safety-risks page, it was not on the agenda when the Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026, and it is not among the substances announced for the next meeting. The FDA has not evaluated it in either direction. It is prepared by a licensed pharmacy for an individual prescription, and compounded medications are not FDA approved.

There is no human safety data for SLU-PP-332. The mouse studies, including eight weeks in old animals, did not describe overt toxicity at the doses used. Two cautions are specific to it: ERRα is also a well-studied regulator of metabolism inside cancer cells, so a personal history of cancer belongs on the intake, and the compound acts on the heart's fuel metabolism, so a cardiac history does too. It is not used in pregnancy or breastfeeding. For tested athletes, WADA prohibits exercise mimetics and metabolic modulators as a class, detection methods were published in 2026, and the 2027 Prohibited List names SLU-PP-332 under S4.4; see do peptides show up on a drug test.

It is a single vial only: not in a blend, and not a pen or capsule. It is injected because the published pharmacology reports that it lacks oral bioavailability. The price is all-in, covering medication, physician review, refill management and shipping, with no separate membership fee. Pepti is cash-pay and does not bill insurance. Vials are multi-dose solutions shipped ready to use, refrigerated with ice packs, with sterile syringes and alcohol prep pads. Refills run every 28 days, one vial per fill. Your physician sets your directions after reviewing your intake, and they are printed on the vial.

When something else makes more sense

SLU-PP-332 cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and side effects.

Pepti prescribes SLU-PP-332 in every state except Oklahoma, plus DC The step-by-step page is how to get SLU-PP-332 prescribed online.